This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013
One systematic review, two randomized controlled trials, and four non-randomized studies were identified regarding the clinical effectiveness of intravenous (IV) ketamine for the treatment of chronic regional pain syndrome. No health technology assessments, systematic reviews, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness of IV ketamine for the treatment of fibromyalgia or reflex sympathetic dystrophy.
Subject indexing assigned by CRD
Administration, Intravenous; Humans; Ketamine; Pain Management
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published